Development and optimization of solid lipid nanoparticle formulation for ophthalmic delivery of chloramphenicol using a Box-Behnken design by Hao, Jifu et al.
© 2011 Hao et al, publisher and licensee Dove Medical Press Ltd. This is an Open Access article  
which permits unrestricted noncommercial use, provided the original work is properly cited.
International Journal of Nanomedicine 2011:6 683–692
International Journal of Nanomedicine Dovepress
submit your manuscript | www.dovepress.com
Dovepress 
683
OrIgINAL reseArcH
open access to scientific and medical research
Open Access Full Text Article
DOI: 10.2147/IJN.S17386
Development and optimization of solid lipid 
nanoparticle formulation for ophthalmic delivery 
of chloramphenicol using a Box-Behnken design
Jifu Hao1
Xinsheng Fang2
Yanfang Zhou3
Jianzhu Wang1
Fengguang guo1
Fei Li1
Xinsheng Peng3
1college of Pharmacy,   Taishan Medical 
University, Taian, Pr china; 2Agronomy 
Department of shandong Agriculture 
University, Taian, Pr china; 3school of 
Pharmaceutical sciences, guangdong 
Medical college, Dongguan, Pr china
correspondence: Xinsheng Peng 
Dongguan songshan Lake National 
High-tech Industrial Development Zone, 
Dongguan, Pr china 523808 
Tel +86-769-22896561 
Fax +86-769-22896560 
email pxsgz@yahoo.com.cn or 
haojifu@163.com
Abstract: The purpose of the present study was to optimize a solid lipid nanoparticle (SLN) of 
chloramphenicol by investigating the relationship between design factors and experimental data 
using response surface methodology. A Box-Behnken design was constructed using solid lipid 
(X1), surfactant (X2), and drug/lipid ratio (X3) level as independent factors. SLN was   successfully 
prepared by a modified method of melt-emulsion ultrasonication and low temperature-
  solidification technique using glyceryl monostearate as the solid lipid, and   poloxamer 188 as 
the surfactant. The dependent variables were entrapment efficiency (EE), drug loading (DL), 
and turbidity. Properties of SLN such as the morphology, particle size, zeta potential, EE, DL, 
and drug release behavior were investigated, respectively. As a result, the nanoparticle designed 
showed nearly spherical particles with a mean particle size of 248 nm. The polydispersity index 
of particle size was 0.277 ± 0.058 and zeta potential was −8.74 mV . The EE (%) and DL (%) 
could reach up to 83.29% ± 1.23% and 10.11% ± 2.02%, respectively. In vitro release studies 
showed a burst release at the initial stage followed by a prolonged release of chloramphenicol 
from SLN up to 48 hours. The release kinetics of the optimized formulation best fitted the 
Peppas–Korsmeyer model. These results indicated that the chloramphenicol-loaded SLN could 
potentially be exploited as a delivery system with improved drug entrapment efficiency and 
controlled drug release.
Keywords: chloramphenicol, solid lipid nanoparticle, Box-Behnken design, melt-emulsion 
ultrasonication and low temperature-solidification technique
Introduction
Nanoparticulate carrier systems (eg, lipid nanoparticles, liposomes, and   microemulsions) 
have recently been under consideration for topical ophthalmic drug delivery because 
they offer the possibility of modulating drug release, by facilitating its transport to the 
different compartments of the eye,1 by increasing corneal penetration, and prolonging 
residence time at ocular surface, thus becoming attractive vehicles for the treatment 
of some ocular diseases.
Among these nanocarrier drug delivery systems, current trials utilizing solid lipid 
nanoparticles (SLN) as alternative drug delivery systems appear very promising.2,3 
SLN, introduced in 1991, represents an alternative carrier system to traditional   colloidal 
  carriers, such as emulsion, liposome, and polymeric micro-and nanoparticles.4 The 
main advantages of SLN over other traditional drug carriers are good   biocompatibility, 
lower cytotoxicity, drug targeting, good production scalability, modulating drug release, 
and the possibility of production on a large industrial scale.5–7International Journal of Nanomedicine 2011:6 submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
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A pharmaceutical formulation development study 
requires a detailed understanding of the relationship between 
process parameters and quality attributes. In particular, it 
is necessary to establish a science-based rationale and a 
design space to identify multidimensional combinations 
of the many causal factors that determine target quality.8 
  However, it is difficult (and inefficient) to obtain an optimized 
formulation with rapid and complete dissolution using a 
traditional formulation screening and optimization process 
(one-factor-at-a-time). The one-factor-at-a-time optimization 
also ignores interaction between factors and may call for an 
unnecessarily large number of runs.9 Currently more and 
more attention has been paid to the formulation optimization 
in the course of establishing SLN dispersion systems. Some 
studies10–12 have optimized nanoparticulate formulations 
using factorial design. It is widely accepted that the choice of 
lipids and emulsifiers and their concentration strongly influ-
ence the quality of SLN dispersions. The character of SLN is 
controlled by the relative amount of oil, surfactant, and the 
ratio of solid lipid to drugs in the formulation. Consequently, 
an important aspect of SLN production, is the design of an 
optimized pharmaceutical formulation, because the ingredi-
ents significantly affect the physicochemical properties and 
drug-release profiles of the nanoparticles.
Nowadays, various experimental designs13–15 are useful 
in developing a formulation requiring less experimentation 
and providing estimates of the relative significance of differ-
ent variables. In recent times, the application of a statistical 
experimental design to pharmaceutical formulation has been 
demonstrated to be efficient at acquiring the necessary infor-
mation to understand the relationship between independent 
and dependent variables in a formulation. The response 
surface methodology (RSM) is useful in simultaneously ana-
lyzing process variables when variable interactions are very 
complicated. Many studies have demonstrated the value of 
RSM for establishing the optimal formulation in various drug 
delivery systems.16 This study used the   Box-Behnken design, 
an RSM design, because it requires fewer runs in a 3-factor 
experimental design than all other RSM designs, and is 
particularly useful when extreme treatment   combinations 
need to be avoided.
The aim of this research was to evaluate the main and 
interaction effect of compositional variation and to   optimize 
the chloramphenicol-loaded SLN formulation using the 
  Box-Behnken design. In this study, in order to prepare SLN, 
a non-polar lipid glyceryl monostearate (GMS) was selected as 
solid lipid by reason of its high drug entrapment   efficiency.17 
Poloxamer 188 as a nonionic surfactant was   chosen as 
an emulsifier. Chloramphenicol was used as a model drug to 
be encapsulated in the SLN.   Chloramphenicol-loaded SLN 
was tailored by a method of melt-emulsion ultrasonication 
and low temperature solidification technique. The physico-
chemical properties such as surface morphology, particle 
size, zeta potential, entrapment efficiency, drug loading, and 
drug release behavior of chloramphenicol-loaded SLN were 
investigated in detail.
Material and methods
Materials
The powered chloramphenicol (purity 99%) was purchased 
from Nanjing Bai Jingyu Pharmaceutical Co. Ltd. (China). 
GMS was provided by Shanghai Chemical Reagent Co., 
Ltd. (China). Poloxamer 188 was a kind gift from BASF 
(Germany). Methanol was of high performance liquid chro-
matography (HPLC) grade. All other reagents and solvents 
were of analytical reagent grade.
Preparation of sLN
SLN was prepared according to previous articles with some 
modification8,18 by the following melt-emulsion ultrasonica-
tion and low temperature-solidification methods. In brief, 
aqueous and oil phases were separately prepared in glass vials. 
Drug and a specified amount of GMS were dissolved in a spec-
ified volume of ethanol (2 mL) and heated above the melting 
temperature of GMS (70°C). Hydrophilic surfactants and dou-
ble distilled water were mixed at 70°C and added to the melted 
oil phase. The resulting suspension was continually stirred by 
mechanical agitation (DC-40, Hangzhou Electrical Engineer-
ing Instruments, China) at 400 rpm for 15 minutes at 70°C. 
The original warm emulsion was further treated for 5 minutes 
(work 2 seconds and stand 3 seconds) by a Lab ultrasonic cell 
pulverizer (JY92-II, Ningbo Scientz Biotechnology Co., Ltd. 
China) at 600 W to form a nanoemulsion. This was rapidly 
cooled by immersing the beaker into icy water (0°). Agitation 
continued until the nanoemulsion yielded a uniform disper-
sion of nanoparticles.
experimental design
In this study, a 17-run, 3-factor, 3-level Box-Behnken 
design was employed to construct polynomial models for 
the optimization process, because it requires few runs with 
3 or 4 variables. This design was suitable for investigating 
the quadratic response surface and for constructing a second-
order polynomial model using Design-Expert software (Trial 
Version7.1.6, Stat-Ease Inc., MN).The design consisted 
of replicated center points and a set of points lying at the International Journal of Nanomedicine 2011:6 submit your manuscript | www.dovepress.com
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  midpoints of each edge of the multidimensional cube, which 
defined the region of interest used to evaluate the main effects, 
interaction effects, and quadratic effects of the   formulation 
ingredients, and to optimize the formulation. The non-linear 
quadratic model generated by the design was:
Y = A0 + A1X1 + A2X2 + A3X3 + A4X1X2 + A5X2X3 + A6X1X3 + 
A7X1
2 + A8X2
2 + A9X3
2, in which Y is the measured response 
of the dependent variables associated with each factor-level 
combination; A0 − A1 are the regression coefficients of the 
respective variables and their interaction terms computed 
from the observed experimental values of Y; and X1, X2, X3 
are the coded levels of independent variables. The term X1 X2 
and Xi
2 (i = 1, 2 or 3) represent the interaction and quadratic 
terms respectively.19 Factors evaluated in this study were the 
amount of GMS (X1), concentration of poloxamer (X2) and the 
ratio of drug/lipid (X3) as the independent variables which were 
represented by −1, 0 and +1, analogous to the low, middle, and 
high values respectively as described in Table 1. The studied 
dependent responses were entrapment efficiency (EE%) (Y1), 
drug loading (DL%) (Y2), turbidity (NTU) (Y3) with constraints 
applied as described in Table 1. The experiment design matrix 
generated by the software was shown in Table 2.
Entrapment efficiency and drug loading 
determination
The content of chloramphenicol was determined by the high 
performance liquid chromatography method. The chromato-
graphic system consisted of a Shimadzu LC-10AT solvent 
delivery pump (Kyoto, Japan) equipped with a 20 µL loop and 
a UV visible detector. A Kromosil (250 × 4.6 mm) analyti-
cal column was used. The eluate was monitored at 275 nm. 
The mobile phase was methanol and water (45:55, v/v) 
with a flow speed of 1.0 mL ⋅ min−1 at room temperature. 
The calibration curve of peak area against concentration of 
chloramphenicol (mg ⋅ L−1) is shown in equation (1):
 A  = 42832C + 3234.7  (1)
It fit over the range 3.2–32 mg ⋅ L−1 with a correla-
tion   coefficient of r = 0.9999 (where A = peak area and 
C = chloramphenicol concentration).
To determine entrapment efficiency and drug loading, 
at first, the appropriated SLN was precipitated by adding 
saturated NH4SO4 solution, and then collecting the serum and 
solid residue, respectively after centrifugation (CS120GXL, 
Hitachi, Japan) at 50,000 rpm for 15 minutes. The solid 
residue was dispersed in 40 mL phosphate buffered saline 
(PBS) solution (pH 7.4), in order to dissolve the free drug 
absorbed on the surface of nanoparticles, and then centrifuge-
separated. Both the drug content in serum and that in PBS 
determined by HPLC were labeled as Wfree. The efficiency of 
drug encapsulation (EE) and drug loading of nanoparticles 
were calculated according to equations (2) and (3),
 
EE
WW
W
totalf ree
total
=
−
×100%  (2)
 
DL
WW
WWW
totalf ree
totalf ree lipid
=
−
−+
×100%  (3)
where Wtotal, Wlipid were the weight of drug added in the 
system, and the weight of lipid added in the system, 
respectively.
Turbidity measurements
For the same samples used in the particle size analysis, 
measurements of turbidity represent the effect of suspended 
solids blocking the transmission of light through a body of 
water, which can be used as an indirect way to determine 
Table 1 Variables and their levels in the Box-Behnken design
Levels
–1 0 1
Independent variables
X1 = Amount of lipid (w/v) 5% 7.5% 10%
X2 = Amount of surfactant (w/v) 2% 5% 8%
X3 = Drug/lipid ratio (w/w) 5% 10% 15%
Dependent variables Constraints
Y1 = Entrapment efficiency (EE%) Maximize
Y2 = Drug loading (DL%) Maximize
Y3 = Turbidity (NTU) Minimize
Table 2 Box-Behnken experimental design
Formulation Lipid 
(w/v, X1)
Surfactant 
(w/v, X2)
Drug/lipid ratio 
(w/w, X3)
1 5% 2% 10%
2 10% 8% 10%
3 5% 8% 10%
4 5% 5% 15%
5 7.5% 5% 10%
6 10% 2% 10%
7 7.5% 5% 10%
8 7.5% 5% 10%
9 7.5% 2% 5%
10 7.5% 5% 10%
11 10% 5% 15%
12 7.5% 5% 10%
13 5% 5% 5%
14 7.5% 2% 15%
15 10% 5% 5%
16 7.5% 8% 5%
17 7.5% 8% 15%International Journal of Nanomedicine 2011:6 submit your manuscript | www.dovepress.com
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particle size in the dispersion system. Dispersion   turbidity 
in nephlometric turbidity units (NTU) was measured using a 
WZS-185 high turbidity Spectrometer (Shanghai Precision & 
Scientific Instrument Co., Ltd, China). All the containers 
used were cleaned thoroughly. All studies were repeated 
as duplicates, with good agreement being found among 
measurements.
Particle size and zeta potential analysis
The particle size and zeta potential of optimum SLN   dispersions 
were measured by Zetasizer (3000SH, Malvern Instruments 
Ltd., UK). All samples were diluted with double distilled water 
to reach a suitable concentration before measurement.
scanning electron microscopy (seM) 
analysis
Scanning electron micrographs were performed using a 
KYKY-1000B scanning electron microscope (KYKY technol-
ogy development Ltd., China). A drop of the SLN dispersion 
was mounted on aluminium stubs covered with a glass lamella, 
air-dried, gold coated under vacuum, then examined.
In vitro release study
The formulation was subjected to in vitro release studies 
using 150 mL of artificial tear fluid (ATF) pH 7.4 as dissolu-
tion medium (maintained at 37 ± 0.5°C), which is equivalent 
to the pH of the eye. In vitro release studies were performed 
using the dialysis bag method, modified to maintain a sink 
condition and achieve satisfactory reproducibility. Two mL 
of chloramphenicol-loaded SLN dispersion was first poured 
into the dialysis bag (molecular weight cut off 12000–14000) 
with the two ends fixed by thread and placed into the pre-
heated dissolution media. The suspension was stirred at 
37 ± 0.5°C, using a RCZ-8A Drug Dissolution Tester (Tianjin 
Medical Instrument Factory, China) with paddle rotating at 
50 rpm. Five mL of the sample was withdrawn at fixed time 
intervals and the same volume of fresh medium was added 
accordingly. Samples were analyzed by HPLC as described 
above. The composition of ATF used was: sodium chloride 
0.670 g, sodium bicarbonate 0.200 g, calcium chloride 
  dihydrate 0.008 g, and purified water q.s. 100 mL.20
Results and discussion
statistical analysis of experimental 
data by Design-expert software
The results of the experimental design were analyzed using 
Design-Expert software, which provided considerable 
useful information and reaffirmed the utility of statistical 
design for conduct of experiments. The selected indepen-
dent variables including the amount of GMS, concentra-
tion of poloxamer 188, and drug/lipid ratio, significantly 
influenced the observed responses for EE (%), DL (%) and 
turbidity, which are presented in Table 3. Polynomial equa-
tions involving the main effect and interaction factors were 
determined based on estimation of statistical parameters 
such as multiple correlation coefficient, adjusted multiple 
correlation coefficient, and the predicted residual sum of 
squares generated by Design-Expert software. The statistical 
validation of the polynomial equations was established by 
ANOVA provision available in the software. Therefore, the 
optimum values of the variables were determined according 
to the obtained experimental data using the Design-Expert 
software, based on the constrained criterion of desirability 
presented in Table 1.21
Response surface analyses plotted in three-dimensional 
model graphs for depicting the effects of the predetermined 
factors on the response of the entrapment efficiency, drug 
loading, and turbidity are shown in Figures 1 to 6, based 
on the model polynomial functions, to assess change in the 
response surface. The response surface plots were used to 
study the interaction effects of 2 independent variables on 
the responses or dependent variables, when a third factor 
is kept at constant level.22 When these plots were carefully 
observed, the qualitative effect of each variable on each 
response parameter could be visualized.
Effects on Entrapment efficiency (Y1)
The entrapment efficiency varies from 30.13% (formula-
tion 4) to 80.77% (formulation 16) for various factor level 
combinations (Table 3). The independent factors affecting 
the entrapment efficiency were the amount of GMS (X1) 
and surfactant levels (X2) (P , 0.05, Table 4 and Figure 1). 
The effect can be explained by the following quadratic 
equation:
Y1 = 65.68 + 8.72X1 + 14.61X2 − 0.25X3  
     − 3.24X1X2 + 8.78X1X3 − 6.6X2X3 
  − 4.64X1
2 + 0.17X2
2 − 3.69X3
2  (4)
The positive value before a factor in the regression equa-
tion indicates that the response increases with the factor and 
vice versa.23 The value of the correlation coefficient (r2) of 
equation 4 was found to be 0.9396, indicating a good fit.
In Figure 1, the effect of varying the amount of lipid and 
emulsifier on the entrapment efficiency (Y1) was studied when 
the drug/lipid ratio was kept constant. The lipid level (X1) International Journal of Nanomedicine 2011:6 submit your manuscript | www.dovepress.com
Dovepress 
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had a significant and positive effect on Y1 as revealed by the 
positive value in the quadratic equation. The result showed 
that the entrapment efficiency rapidly increased as the amount 
of lipid increased. Increasing the amount of GMS, was bound 
to increase the % of EE because of the increased concentra-
tion of mono-, di-, and triglycerides, which act as solubiliz-
ing agents for highly lipophilic drugs and provide more 
and more spare space to accommodate excessive drugs.24 
However increasing the amount of drug/lipid ratio while 
keeping the emulsifier level constant, as shown in Figure 2, 
would decrease the entrapment efficiency, probably because 
redundant drug becomes insoluble in GMS.
The entrapment efficiency could be increased with drug 
concentration (X3) in the internal phase as more of the drug 
would be available for entrapment. The surfactant level (X2) 
also has a significant and positive effect on the entrapment 
efficiency (Y1). In Figure 3, the entrapment efficacy was 
  significantly increased by increasing the amount of   emulsifier 
and the amount of lipid. This effect was, probably due to 
the increased viscosity of the medium, because increasing 
the amount of lipid resulted in faster solidification of the 
nanoparticles. This would also prevent drug diffusion to the 
external phase of the medium.25 As the percentage of emulsi-
fier increased, part of the chloramphenicol was incorporated 
in the surfactant layer at the surface of the SLN, leading to 
a high entrapment efficacy.
effects on drug loading (Y2)
According to the results obtained from the experiments for 
drug loading, the value of drug loading varied from 1.79% 
(formulation 9) to 10.29% (formulation 11) (Table 3). The 
%DL was clearly influenced by surfactant concentration and 
Table 3 Observed and predicted value of encapsulation efficiency (Y1), drug loading (Y2) and turbidity (Y3) of formulations in the 
  Box-Behnken design
Formulation Observed Y1 Predicted Y1 Observed Y2 Predicted Y2 Observed Y3 Predicted Y3
1 41.26 34.64 3.95 4.04 32 36.5
2 74.68 81.30 6.96 6.88 26 21.5
3 75 70.35 6.95 6.79 42 50
4 30.13 39.60 4.32 5.39 24 15.5
5 63.68 65.68 5.98 6.16 35 35.6
6 53.91 58.56 5.11 5.27 124 116
7 67.32 65.68 6.32 6.16 33 35.6
8 67.53 65.68 6.32 6.16 38 35.6
9 36.38 41.20 1.79 2.68 69 68.5
10 63.11 65.68 5.92 6.16 26 35.6
11 76.4 74.60 10.29 11.28 39 43
12 66.74 65.68 6.24 6.16 46 35.6
13 55.85 57.65 7.74 6.76 23 19
14 56.75 53.90 7.84 6.69 62 66
15 67.01 57.54 3.26 2.20 34 42.5
16 80.77 83.62 3.88 5.02 31 27
17 74.74 69.92 9.61 8.72 26 26.5
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Figure 1 response surface plot showing effect of the amount of lipid (X1) and 
surfactant levels (X2) on entrapment efficiency (Y1).
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Figure 2 response surface plot showing effect of the amount of lipid (X1) and drug/
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the drug/lipid ratio as seen in Table 4. The following equation 
can explain the effect of factor levels on %DL:
Y2 = 6.16 + 0.33X1 + 1.09X2 + 1.93X3 − 0.28X1X2
  + 2.61X1X3 − 0.079X2X3 + 0.11X1
2
  − 0.52X2
2 + 0.14X3
2 (r = 0.9430)  (5)
The main effects of X1, X2, and X3 represent the average 
result of changing 1 variable at a time from its low level to 
its high level. The negative coefficients before independent 
variables indicate an unfavorable effect on the %DL, while the 
positive coefficients indicate a favorable effect on the %DL. 
The interaction terms (X1X2, X1X3, X2X3, X1
2, X2
2, and X3
2) show 
how the %DL changes when 2 variables are simultaneously 
changed. Analyzing these coefficients in the above second-
order polynomial mode shows how the increase of drug/lipid 
ratio and emulsifier level enhances the drug loading of SLN, 
making it more efficient than for GMS because of the positive 
and large coefficient of these particles. The cross-interaction 
of GMS and drug/lipid ratio on %DL of SLN was   significant 
because the coefficient of X1X3 was larger than others. 
  Furthermore, the F-value for the full quadratic equation for 
the %DL of SLN was 6.25, indicating that the second-order 
response surface model was significant at the 5% level. Among 
the 3 independent variables, the lowest coefficient value is for 
X1 (A1 = 0.22 and P . 0.05), indicating that this variable is 
insignificant in prediction of drug loading.
By analyzing the response surfaces for drug loading, it 
was obvious that the level of drug/lipid ratio and emulsifier 
exert positive influence on drug loading. As Figure 4 shows, 
an increse of lipid and emulsifier concentration leads to a 
non-linear increase in drug loading when the drug/lipid ratio 
is fixed. When the amount of surfactant is increased, the 
percent of DL is thought to increase because of enhanced 
entrapped drug; the reason why DL% is increased on the 
enhanced lipid is that the increased content of lipids can 
provide more and more spare space to accommodate exces-
sive drugs. At the same time, according to equation (3)   
and Figure 5, for constant amount of surfactant concentration, 
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Figure 4 response surface plot showing effect of the amount of lipid (X1) and 
surfactant levels (X2) on drug loading (Y2).
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Figure 5 response surface plot showing effect of the amount of lipid (X1) and 
drug/lipid ratio (X3) on drug loading (Y2).
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Figure 6 response surface plot showing effect of the amount of lipid (X1) and 
surfactant levels (X2) on turbidity (Y3).
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Figure 3 response surface plot showing effect of the amount of surfactant (X2) and 
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when drug concentration increases, the amount of excipients 
increases, which results in reduced drug loading.
effects on turbidity (Y3)
Turbidity could have caused some obstruction when light 
was transmitted to a suspension. Turbidity value depends 
significantly on the particle size and thus can be used indi-
rectly to reflect particle size. The turbidity of SLN ranged 
from 23 NTU (formulation 14) to 124 NTU (formulation 8) 
(Table 3) with the selected levels of variables. Small-sized 
particles are highly desirable in order to increase the 
permeability through cornea surface. Results in Table 4 
demonstrated that turbidity was significant but negatively 
dependent upon the surfactant level. The full second-order 
polynomial model for turbidity obtained by the response 
surface regression procedure using Design-Expert software 
is given by:
Y3 = 35.6 + 12.75X1 − 20.25X2 − 0.75X3
	−  27X1X2 + X1X3 + 0.5X2X3 + 1.7X1
2
  + 18.7X2
2 − 7.3X3
2 (r = 0.9693)  (6)
By analyzing these coefficients in the above second-
order polynomial mode, turbidity is distinctly influenced by 
surfactant concentration and lipid ratio as seen in Table 4; 
the cross-interaction of poloxamer 188 and GMS on the 
size of SLN was significant because the coefficient of X1X2 
was far greater than others. Furthermore, the F-value for the 
full quadratic equation for the SLN particle size was 12.07, 
indicating that the second-order response surface model was 
significant at the 5% level.
As Figure 6 shows, the increase in emulsifier could 
efficiently reduce the particle size of SLN. On increasing 
the concentration of poloxamer 188, the particle size was 
decreased. This might be due to the surfactant-induced 
reduction in surface tension between the aqueous phase and 
organic phase. In addition, surfactant helps to stabilize the 
newly generated surfaces and prevents particle   aggregation.26 
The increase in GMS concentration would lead to the 
increase in size. The fact that the size of lipid nanoparticles 
is highly dependent on lipid concentration can be explained 
in terms of the tendency of the lipid to coalesce at high lipid 
concentration. According to Stoke’s law, this behavior can 
be explained by a difference in density between the internal 
and external phases.27
Optimization and validation
The desirability function was probed using Design-Expert 
software to acquire the optimized formulation. The   optimum 
formulation was based on the set criteria of maximum entrap-
ment efficiency, maximum drug loading, and minimum par-
ticle size. Therefore a new batch of SLN with the predicted 
levels of formulation factors was prepared to confirm the 
validity of the optimization procedure. The composition of 
optimized formulation was achieved with 10% (w/v) GMS, 
8% (w/v) surfactant and 13.5 mg/mL chloramphenicol, which 
fulfill the requirements of optimization. The optimized for-
mulation has entrapment efficiency 83.29% ± 1.23%, drug 
loading 10.11% ± 2.02%, and turbidity 21 ± 3 NTU, which 
were in good agreement with the predicted values.
Physicochemical characterization  
of nanoparticles
SEM studies revealed that chloramphenicol-loaded SLN were 
almost spherical in shape with smooth morphology which 
appeared as white bright dots (Figure 7). However, in order 
to obtain more precise information on the size   distribution, 
particle size and zeta potential, measurements were per-
formed in the following study.
Table 4 Statistical analysis results of entrapment efficiency, drug loading, and turbidity
Parameters Entrapment efficiency (Y1) Drug loading (Y2) Turbidity (Y3)
Coefficient P-value Coefficient P-value Coefficient P-value
Intercept 5.8663 0.0147* 6.25 0.0123* 12.07 0.0017*
X1 (5%, 10%) 10.7146 0.0136* 0.72 0.4257 15.41 0.0057*
X2 (2%, 8%) 30.0828 0.0009* 7.76 0.0271* 38.88 0.0004*
X3 (5%, 15%) 0.0087 0.9282 24.20 0.0017* 0.05 0.8240
X1 × X2 0.7408 0.4179 0.26 0.6235 34.56 0.0006*
X1 × X3 5.4282 0.0526 22.29 0.0022* 0.05 0.8339
X2 × X3 3.0690 0.1233 0.02 0.8906 0.01 0.9164
X1
2 1.5953 0.2470 0.04 0.8496 0.14 0.7154
X2
2 0.0023 0.9634 0.92 0.3687 17.45 0.0042*
X3
2 1.0101 0.3484 0.07 0.8021 2.66 0.1470
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It was known that the particle size distribution was one 
of the most important characteristics for evaluation of the 
stability of colloidal systems. The mean particle size (z-ave) 
and the polydispersity index (PI) were 2 measures to  evaluate 
the width of the size distribution. Figure 8 shows that the 
particle size distribution of chloramphenicol-loaded SLN 
was 248 ± 4.8 nm; the polydispersity index of particle size 
was 0.277 ± 0.058 (run 3).
Zeta potential is the measure of overall charges acquired 
by particles in a particular medium and is considered as 
one of the benchmarks of stability of the colloidal system. 
Particles will repel each other if the systems have high posi-
tive or negative value of zeta potential, and a system having 
value ±30 mV is considered a stable formulation if dispersed 
in a liquid as colloidal dispersion.23 In the present study, the 
zeta potential value of optimum formulation was −8.74 mV . 
The absolute value of zeta potential was lower than those 
values reported in the literature. This might be attributed to 
poloxamer 188, a nonionic surfactant which decreases the 
electrostatic repulsion between the particles and sterically 
stabilizes the nanoparticles by forming a coat around their 
surface.28 The negative charge of SLN may result from 
fatty acids released from the hydrolysis of GMS. In such 
a system, the hydrophilic emulsifiers were thought to align 
alongside each other, imparting more rigidity and strength 
to the   emulsifier film through hydrogen bonding.29
In addition, with regard to particle distribution, the 
polydispersity index is an indicator of the homogeneity of 
the size distribution. The PI value of 0.277 indicated that 
the optimal composition could be used to produce a stable 
SLN dispersion with a relatively narrow size distribution for 
chloramphenicol-loaded SNL.
In vitro drug release behavior
The drug release behavior in vitro of chloramphenicol-
loaded SNL was investigated using a dialysis membrane in 
pH 7.4 ATF (37 ± 0.5 ). In Figure 9, free chloramphenicol 
exhibited a rapid release of 90% of drug within 6 hours, 
whereas the release profiles of SNL indicated a biphasic pat-
tern with a burst release during the first 8 hours, followed by 
a sustained release over 48 hours. The initial fast release of 
drug from the SNL could be explained by drug desorption 
from the outer surface of the SNL and the larger specific 
surface of the smaller particles increasing the initial drug 
release rate. Furthermore, SLN had been prepared so as not 
to remove existing free drug, but the initial burst related to 
free drug could not be ignored. The mechanism of release was 
determined by finding the R2 value for each kinetic model viz 
First-order, Higuchi, Peppas–Korsmeye, and Hixon–Crowell 
model corresponding to the release data obtained. The 
  Peppas–Korsmeye model was the best (y = 0.9428 x − 0.9385, 
R2 = 0.9969) in that the R2 value of the Korsmeyer–Peppas 
model is much larger than other kinetic models. Thus it can 
Figure  7  scanning  electron  micrographs  of  chloramphenicol  loaded  solid  lipid 
nanoparticles consisting of glyceryl monostearate 10%, poloxamer 8%, drug/lipid 
ratio13.5% (×5000).
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Figure 8 Particle distribution of chloramphenicol-loaded solid lipid nanoparticles.
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be said that the drug release follows Peppas–Korsmeyer   
model mechanism. The n value is 0.9428 which is above 
0.89, so that the release can be characterized by super case II 
transport,30 which means the drug release rate is dominated 
by polymer disentanglement and erosion.
Conclusion
Optimization of an SLN formulation is a complex process, 
which requires one to consider a large number of variables and 
their interactions with each other. The present study conclu-
sively demonstrates that the optimal formulations of SLN con-
tain 10% (w/v) GSM, 8% (w/v) poloxamer 188, and 13.5 mg/
mL chloramphenicol using the Box-Behnken design. The 
derived polynomial equations and response surface plots aid 
in predicting the values of selected independent variables for 
preparation of optimum formulations with desired properties. 
The chloramphenicol-SLN obtained in vitro release experi-
ments exhibited a biphasic release pattern with burst release 
at the initial phase followed by sustained release. However, 
in vivo studies for chloramphnicol-SLN should be performed 
to determine its ophthalmic delivery efficacy.
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